Table 3.
Percentage of Treated Residents by Anticoagulant Class and Medication
| H1‐2011 | H2‐2011 | H1‐2012 | H2‐2012 | H1‐2013 | H2‐2013 | H1‐2014 | H2‐2014 | H1‐2015 | H2‐2015 | H1‐2016 | H2‐2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n, total | 17 895 | 33 959 | 33 493 | 33 956 | 35 709 | 37 118 | 36 183 | 36 379 | 36 807 | 37 644 | 37 474 | 37 787 |
| Treated, %a | 42.4 | 42.3 | 43.1 | 42.8 | 42.7 | 42.8 | 43.7 | 44.3 | 44.8 | 45.5 | 47.0 | 47.8 |
| Warf., % | 40.5 | 39.4 | 39.4 | 38.4 | 37.0 | 35.2 | 33.6 | 31.8 | 30.6 | 29.0 | 27.3 | 24.7 |
| DOAC, % | 1.9 | 2.9 | 3.7 | 4.3 | 5.6 | 7.7 | 10.2 | 12.5 | 14.2 | 16.5 | 19.7 | 23.1 |
| Dab., %b | 1.9 | 2.9 | 3.3 | 3.1 | 2.7 | 2.6 | 2.7 | 2.6 | Sup. | Sup. | Sup. | 2.2 |
| Riv., % | 0.0 | 0.0 | 0.4 | 1.2 | 2.9 | 4.6 | 6.2 | 7.1 | 7.1 | 7.3 | 7.8 | 8.3 |
| Apix., % | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.5 | 1.3 | 2.8 | 4.7 | 7.0 | 9.8 | 12.6 |
| Edox., %b | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | Sup. | Sup. | Sup. | 0.1 |
Apix. indicates apixaban; Dab., dabigatran; DOAC, direct‐acting oral anticoagulant; Edox., edoxaban; H, half; Riv., rivaroxaban; Warf., warfarin.
a
Treated percentage may not equal the sum of warfarin and DOAC percentages because of rounding.
b
Cell values suppressed to prevent any individual cell size from being <11.